Table 2.
Factors associated with postprogression survival
| Univariate P value | Multivariate P value | |
|---|---|---|
| Age >= 65 (year) | 0.027 | 0.117 |
| Gender | 0.255 | |
| Smoking | 0.911 | |
| Line of tyrosine kinase inhibitor | 0.018 | 0.022 |
| Tumor growth rate (PD or SD) | 0.474 | |
| Mutation type | 0.165 | |
| Number of extracranial lesions | 0.307 | |
| Brain metastases | 0.654 | |
| Immediate chemotherapy | 0.156 | |
| Progressive site | 0.023 | 0.114 |
| Definitive local therapy to metastatic site(s) | 0.111 | |
| Definitive local therapy to primary site(s) | 0.343 | |
| Definitive local therapy to any site(s) | 0.053 | |
| Continuation of tyrosine kinase inhibitor | 0.283 | |
| Longer progression-free survival | 0.602 |
PD: progressive disease; SD: stable disease